期刊
EMBO MOLECULAR MEDICINE
卷 9, 期 2, 页码 219-237出版社
WILEY
DOI: 10.15252/emmm.201505774
关键词
angiogenesis; drug resistance; extracellular matrix; myeloid infiltration; vascular normalization
资金
- Associazione Italiana per la Ricerca sul Cancro (AIRC) [14284, 10104, 15585, 18652]
- AIRC [12182]
- Fondo Investimenti per la Ricerca di Base [RBAP11BYNP, RBFR08F2FS-002]
- Fondazione Cassa di Risparmio di Torino
- University of Torino-Compagnia di San Paolo
The development of resistance remains a major obstacle to long-term disease control in cancer patients treated with targeted therapies. In BRAF-mutant mouse models, we demonstrate that although targeted inhibition of either BRAF or VEGF initially suppresses the growth of BRAF-mutant tumors, combined inhibition of both pathways results in apoptosis, long-lasting tumor responses, reduction in lung colonization, and delayed onset of acquired resistance to the BRAF inhibitor PLX4720. As well as inducing tumor vascular normalization and ameliorating hypoxia, this approach induces remodeling of the extracellular matrix, infiltration of macrophages with an M1-like phenotype, and reduction in cancer-associated fibroblasts. At the molecular level, this therapeutic regimen results in a de novo transcriptional signature, which sustains and explains the observed efficacy with regard to cancer progression. Collectively, our findings offer new biological rationales for the management of clinical resistance to BRAF inhibitors based on the combination between BRAF(V600E) inhibitors with anti-angiogenic regimens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据